Novocure Stock Price, News & Analysis

Novocure (NVCR) will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual SNO Meeting. The presentations include research on newly designed arrays for efficient TTFields delivery in mouse studies, optimal positioning of Head Flexible Electrodes (HFE) for infratentorial brain tumors, and a subgroup analysis of IDH-mutant glioblastoma patients using real-world data from the xCures platform. More than 20 independent studies of TTFields will be presented at the meeting. The company will also host a sponsored symposium on TTFields therapy's impact on patient outcomes.

Novocure (NVCR) has received FDA approval for its new Head Flexible Electrode (HFE) transducer arrays, designed for use with Optune Gio® in treating adult glioblastoma multiforme (GBM). The new arrays feature flexible polymer material instead of ceramic discs, making them one-third lighter and 50% thinner than current arrays. This innovation aims to improve patient comfort during treatment. The company plans to transition U.S. Optune Gio users to the new HFE arrays through the first half of 2025 through a controlled plan.

Novocure (NVCR) has appointed Christoph Brackmann as its next Chief Financial Officer. Brackmann will initially join as Senior Financial Advisor and transition to CFO on January 1, 2025, when current CFO Ashley Cordova becomes CEO. Brackmann joins from Moderna, where he served as Senior Vice President of Finance since 2019, leading the finance team during the COVID-19 pandemic. The 51-year-old executive previously held positions at Shire plc, Eli Lilly, and Novartis, bringing extensive experience in financial leadership and healthcare industry expertise.

Novocure (NVCR) reported Q3 2024 financial results with net revenues of $155.1 million, up 22% year-over-year. The company achieved record 4,113 active patients on therapy and received FDA approval for Optune Lua® for metastatic non-small cell lung cancer treatment. The quarter showed a net loss of $30.6 million ($0.28 per share). Key market revenues included US ($98.3M), Germany ($17.0M), France ($15.2M), and Japan ($8.6M). The company maintains strong liquidity with $959.9 million in cash and investments. CEO Asaf Danziger announced retirement, to be succeeded by CFO Ashley Cordova effective January 2025.

Novocure (NASDAQ: NVCR) announced FDA approval of Optune Lua® for treating adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after platinum-based therapy. Optune Lua is approved for concurrent use with PD-1/PD-L1 inhibitors or docetaxel.

The approval is based on the Phase 3 LUNAR study, which demonstrated a statistically significant 3.3-month extension in median overall survival for patients treated with Optune Lua. Patients receiving Optune Lua with a PD-1/PD-L1 inhibitor showed a remarkable 8.0-month extension in median overall survival compared to PD-1/PD-L1 inhibitor alone.

Optune Lua is a wearable device that delivers Tumor Treating Fields (TTFields), which exert physical forces on dividing cancer cells, resulting in cell death. The treatment showed a favorable safety profile with mostly low-grade skin-related adverse events.

Novocure (NASDAQ: NVCR) has announced that it will release its third quarter 2024 financial results on Wednesday, October 30, 2024, before the U.S. financial markets open. The company's management will host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss the financial results for the three-month quarter and first nine months ending September 30, 2024.

Investors can access the conference call via a registration link that will provide dial-in details. A separate webcast registration link is available for those who prefer to join online. Presentation slides and the corporate presentation will be accessible from Novocure's Investor Relations webpage and will remain available for at least 14 days after the call.

Novocure (NVCR) will present real-world data at ESMO 2024 showing improved survival outcomes for newly diagnosed glioblastoma (ndGBM) patients with increased use of Tumor Treating Fields (TTFields) therapy. The analysis suggests higher TTFields device usage is significantly associated with better survival in a broad ndGBM patient population.

The presentation, titled 'Association of Tumor Treating Fields Device Usage with Survival in Newly Diagnosed GBM: A Real-World Analysis of Patients in the US', will be displayed as Poster #459 on September 16. Novocure has also sponsored an ESMO Colloquium on the role of alternating electric fields in treating advanced non-small cell lung cancer, scheduled for September 16.

Novocure (NASDAQ: NVCR) announced significant leadership changes. CEO Asaf Danziger will retire at the end of 2024 after 22 years, succeeded by current CFO Ashley Cordova on January 1, 2025. Danziger will serve as Senior Advisor into early 2026 and remain on the Board of Directors. Additionally, COO Wilco Groenhuysen will step down on October 1, 2024, with Mukund Paravasthu, currently Senior Vice President of Product Development, transitioning to COO.

These changes mark a significant transition for Novocure, which has grown from a preclinical lab to a global company treating thousands of cancer patients with Tumor Treating Fields therapy. The company aims to expand its therapy to more indications under new leadership.

Novocure (NVCR) has announced its participation in the 2024 Wells Fargo Healthcare Conference on September 4, 2024. Executive Chairman William Doyle will engage in a fireside chat at 4:30 p.m. EST and attend one-on-one investor meetings throughout the event. A live audio webcast of the presentation will be available on Novocure's Investor Relations website and will remain accessible for at least 14 days post-event.

Investors can access Novocure's regularly updated corporate presentation on the company's Investor Relations page. Novocure utilizes this platform to disclose material non-public information and comply with Regulation FD disclosure obligations.